This suggests that AFP could be used together with some of the metabolites identified, to assign patients to high-risk vs. low-risk groups for surveillance, helping the field move toward precision surveillance, where surveillance tests and intervals are tailored to individual HCC risk. This evidence concerns the gene AFP and hepatocellular carcinoma.